Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR alb1 INTEGRIN AND USES

Page 2 of 11

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

- 1-5. (Canceled)
- 6. (Currently Amended) The method of claim [[44]] $\underline{59}$ wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.
- 7-9. (Canceled)
- 10. (Currently Amended) The method of claim [[7]] 58 wherein the antibody is a monoclonal antibody.
- 11. (Currently Amended) The method of claim [[7]] 58 wherein the patient has inflammatory disease or other condition is renal fibrosis or crescentic glomerulonephritis.
- 12-14. (Cancel)
- 15. (Currently Amended) The method of claim [[13]] <u>55</u> wherein the antibody blocks the interaction of α1β1 integrin on peripheral blood monocytes with Collagen XIII on the cell surface of the vascular/capillary endothelial cells of inflamed tissues.
- 16-20. (Canceled)

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR a181 INTEGRIN AND USES

Page 3 of 11

- 21. (Currently Amended) The method of claim [[17]] <u>56</u> wherein the antibody is a monoclonal antibody.
- 22-24. (Canceled)
- 25. (Currently Amended) The method of claim [[23]] <u>57</u> wherein the antibody is a monoclonal antibody.
- 26-44. (Canceled)
- 45. (Currently Amended) The method of claim [[13]] <u>55</u> wherein the antibody is a monoclonal antibody.
- 46. (Currently Amended) The method of claim [[17]] $\underline{56}$ wherein the antibody blocks the interaction of $\alpha 1\beta 1$ integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.
- 47. (Currently Amended) The method of claim [[23]] <u>57</u> wherein the antibody blocks the interaction of α1β1 integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues.
- 48. (Currently Amended) The method of claim [[13]] <u>55</u> wherein the antibody inhibits binding of fluorochrome-conjugated purified α1β1 integrin to MCP-1 treated primary endothelial cells in culture.

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR a 1 \$1 INTEGRIN AND USES

Page 4 of 11

- 49. (Currently Amended) The method of claim [[17]] <u>56</u> wherein the antibody inhibits binding of fluorochrome-conjugated purified α1β1 integrin to MCP-1 treated primary endothelial cells in culture.
- 50. (Currently Amended) The method of claim [[23]] $\underline{57}$ wherein the antibody inhibits binding of fluorochrome-conjugated purified $\alpha 1\beta 1$ integrin to MCP-1 treated primary endothelial cells in culture.
- 51. (Currently Amended) The method of claim [[43]] <u>58</u> wherein the antibody inhibits binding of fluorochrome-conjugated purified α1β1 integrin to MCP-1 treated primary endothelial cells in culture.
- 52. (Currently Amended) The method of claim [[44]] <u>59</u> wherein the antibody inhibits binding of fluorochrome-conjugated purified α1β1 integrin to MCP-1 treated primary endothelial cells in culture.

53-54. (Canceled)

- 55. (Currently Amended) A method of reducing selective efflux of integrin α1β1-positive monocytes into the interstitium of chronically inflamed tissues, the method comprising contacting the α1β1 integrin on peripheral blood monocytes with an antibody to Collagen XIII that interferes with the interaction between Collagen XIII and α1β1 integrin, The method of claim 13 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.
- 56. (Currently Amended) A method of reducing the rate of monocyte efflux into the interstitial space of chronically inflamed tissues, the method comprising contacting the tissue

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR a161 INTEGRIN AND USES

Page 5 of 11

with an antibody to Collagen XIII, wherein the antibody blocks Collagen XIII from binding with α1β1 integrin, and The method of claim 17 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

- 57. (Currently Amended) A method of blocking the interaction of α1β1 integrin on peripheral blood monocytes with Collagen XIII on vascular endothelium of chronically inflamed tissues, the method comprising contacting the monocytes, the vascular endothelium, or both with an antibody to Collagen XIII, The method of claim 23 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.
- 58. (Currently Amended) A method of treating a patient having chronically inflamed kidneys associated with an accumulation of α1β1 integrin positive monocytes in the interstitium, the method comprising administering to the patient an antibody to Collagen XIII, wherein the antibody reduces the rate of efflux of α1β1 integrin positive monocytes into the renal interstitium, and The method of claim 43 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.
- 59. (Currently Amended) A method of treating a patient having renal fibrosis, the method comprising administering to the patient an antibody to Collagen XIII, wherein the antibody prevents the binding of Collagen XIII to α1β1 integrin positive monocytes, and The method of claim 44 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:1.

60-61. (Canceled)

62. (Withdrawn/Currently Amended) The method of claim [[13]] 55 wherein the autibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

Page 6 of 11

- 63. (Withdrawn/Currently Amended) The method of claim [[17]] 56 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.
- 64. (Withdrawn/Currently Amended) The method of claim [[23]] 57 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.
- 65. (Withdrawn/Currently Amended) The method of claim [[43]] 58 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.
- 66. (Withdrawn/Currently Amended) The method of claim [[44]] 59 wherein the antibody binds to a peptide fragment of Collagen XIII, the peptide fragment having SEQ ID NO:2.
- 67. (Cancelled)
- 68. (Currently Amended) The method of claim [[13]] $\underline{55}$ wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.
- 69. (Currently Amended) The method of claim [[17]] $\underline{56}$ wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.
- 70. (Currently Amended) The method of claim [[23]] 57 wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR albi INTEGRIN AND USES

Page 7 of 11

- 71. (Currently Amended) The method of claim [[44]] <u>59</u> wherein the antibody reduces the rate of efflux of $\alpha 1\beta 1$ integrin positive monocytes into the interstitial space at the site of inflammation.
- 72. (New) The method of claim 59 wherein the antibody is a monoclonal antibody.
- 73. (New) The method of claim 55, wherein the antibody binds to a polypeptide, said polypeptide consisting of a peptide fragment of Collagen XIII, said polypeptide consisting of 8 to 16 amino acid residues, and said polypeptide having SEQ ID NO:1.
- 74. (New) The method of claim 63 wherein the antibody binds to a polypeptide, said polypeptide consisting of SEQ ID NO:2 or said polypeptide consisting of SEQ ID NO:2 with a deletion of one amino acid residue from one or both termini.